Liwei Yu, Raquel Neves, Martijn M Bos, David J Tester, Mayank Sardana, John R Giudicessi, Michael J Ackerman
{"title":"Evaluation of CACNA1C-Positive Patients Evaluated in a Tertiary Genetic Heart Rhythm Clinic.","authors":"Liwei Yu, Raquel Neves, Martijn M Bos, David J Tester, Mayank Sardana, John R Giudicessi, Michael J Ackerman","doi":"10.1007/s12265-025-10638-7","DOIUrl":"https://doi.org/10.1007/s12265-025-10638-7","url":null,"abstract":"<p><p>Genetic variants in CACNA1C are associated with several cardiac and neurologic conditions. We conducted a retrospective review of patients evaluated and treated who presented with a pathogenic (P), likely pathogenic (LP), or variant of uncertain significance (VUS) in CACNA1C. Among 4,774 patients, 49 had P, LP, or VUS variants (55% female; median age 15 years; mean QTc 481 ms). Of these, 22 had long QT syndrome type 8, 8 had Timothy syndrome, 2 had cardiac only Timothy syndrome, and 9 had no cardiac phenotype. Ten patients exhibited extracardiac findings. Thirty-one patients were treated with a beta-blocker, 21 patients had an implantable cardioverter-defibrillator (ICD). Nine patients were on intentional non-therapy. Six patients had at least 1 breakthrough cardiac event on follow-up. Overall, CACNA1C-positive patients present with diverse diagnoses and severity. Treatments vary by phenotype, however management with preventative measures only presents a reasonable option for some phenotype-negative, genotype-positive patients.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yihua Wang, Qiang Yue, Xiurong Song, Wei Du, Rui Liu
{"title":"Hypoxia/reoxygenation-induced Glycolysis Mediates Myocardial Ischemia-reperfusion Injury Through Promoting the Lactylation of GPX4.","authors":"Yihua Wang, Qiang Yue, Xiurong Song, Wei Du, Rui Liu","doi":"10.1007/s12265-025-10628-9","DOIUrl":"https://doi.org/10.1007/s12265-025-10628-9","url":null,"abstract":"<p><p>Myocardial ischemia-reperfusion injury (MIRI) is an injury mechanism of myocardial infarction, related to ferroptosis and glycolysis. Lactate produced by glycolysis promotes protein lactylation. This study aimed to investigate the correlation between glycolysis, ferroptosis, and GPX4 lactylation in MIRI. Hypoxia/reoxygenation (H/R) increased glucose uptake, lactate production, ECAR, OCR, LDH release, lipid ROS, Fe<sup>2+</sup>, GSH, MDA contents, and cell apoptosis, and decreased GSH level in the H9C2 cells, suggesting H/R promoted glycolysis and ferroptosis. 2-DG treatment relieved the H/R-induced injury, while lactate treatment aggravated it. Besides, 2-DG suppressed lactylation of GPX4 at K218 and K228 sites and increased its protein stability. GPX4 overexpression relieved the injury caused by H/R, and alleviated cardiac injury, decreased cardiomyocyte ferroptosis in heart tissues of MIRI rats. In conclusion, GPX4 lactylation facilitated H/R-induced cardiomyocyte injury and aggravated MIRI in rats. Our findings provided new insight into targeting glycolysis and GPX4 lactylation as therapeutic strategies of MIRI.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mia Bonini, Surya Sanjay, Maximilian Balmus, Alexander Makkinejad, Katelyn Monaghan, Marc Hirschvogel, Nicholas Burris, Bo Yang, David Nordsletten
{"title":"Modeling the Hemodynamic Impact of Y-incision Aortic Annular Enlargements on Aortic Valve Replacement and Valve-in-Valve Procedures.","authors":"Mia Bonini, Surya Sanjay, Maximilian Balmus, Alexander Makkinejad, Katelyn Monaghan, Marc Hirschvogel, Nicholas Burris, Bo Yang, David Nordsletten","doi":"10.1007/s12265-025-10634-x","DOIUrl":"https://doi.org/10.1007/s12265-025-10634-x","url":null,"abstract":"<p><p>Y-incision aortic annular enlargement (Y-AAE) with surgical aortic valve replacement (SAVR) may improve outflow tract hemodynamics and valve-in-valve (ViV) outcomes but could increase thrombosis risk. We used computational fluid dynamics to analyze post-operative hemodynamics in 15 patient-specific SAVR models, comparing cases with and without Y-AAE. ViV scenarios were simulated by virtually deploying transcatheter aortic valves. Transvalvular peak velocities, pressure gradients, and blood residence time (a proxy for hemostatic risk) were analyzed to assess performance across cases. Y-AAE reduced peak velocity by 39.3% (55% in ViV), transvalvular pressure gradient by 87.2% (92% in ViV), and mean blood residence time by 10.3% (14% in ViV), with no consistent difference in maximum residence time. SAVR with Y-AAE demonstrated improved hemodynamics, even with ViV procedures, and no evidence of increased thrombosis risk.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Craig M Stolen, Molly E Kupfer, Karen Tomes, Sean Horan, Ananta Pandey, Julie Snodie, Kate Frost, Shawn Merhaut
{"title":"Redesign of Implantable Cardiac Device Workflow Improves Remote Monitoring Timeliness and Heart Failure Alert Metrics.","authors":"Craig M Stolen, Molly E Kupfer, Karen Tomes, Sean Horan, Ananta Pandey, Julie Snodie, Kate Frost, Shawn Merhaut","doi":"10.1007/s12265-025-10632-z","DOIUrl":"https://doi.org/10.1007/s12265-025-10632-z","url":null,"abstract":"<p><p>Integration into clinical workflow remains a barrier to realizing the benefits of remote heart failure monitoring technologies. A workflow redesign program was conducted at 27 cardiology sites to improve implementation of heart failure remote monitoring with HeartLogic. Device data was retrospectively retrieved from HeartLogic-capable ICDs and CRT-Ds for the 12-month periods before and after re-design. Workflow redesign led to a decrease in HeartLogic enablement time (28±110 to 10±31 days, p<0.0001) and reduction in delayed data transmissions (10% to 6%). The number of HeartLogic alert onsets per year was unchanged; however, the length of individual alerts decreased from pre- to post-redesign (47.6±38.4 to 44.1±36.5 days, p=0.001) as did the percentage of time patients spent in alert (15.5±19.9% to 14.3±19.0%, p=0.04). The maximum HeartLogic index values per alert were also lower post-redesign (28.9±12.8 vs 27.8±12.1, p=0.001). Workflow redesign improved remote monitoring utilization and heart failure alert metrics.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exercise Empowerment: A Multifaceted Anatomy in Managing Diabetic Myocardial Disorder.","authors":"Congfei Chen, Longfei Xu, Kun Wang, Tianhui Wang","doi":"10.1007/s12265-025-10630-1","DOIUrl":"https://doi.org/10.1007/s12265-025-10630-1","url":null,"abstract":"<p><p>Diabetic myocardial disorder is characterized by myocardial dysfunction in diabetes mellitus patients, independent of other heart disease causes like coronary artery disease or hypertension. This condition threatens the well-being of patients. At the cellular and molecular levels, disruptions in cardiomyocyte metabolism, abnormal calcium signaling, and increased reactive oxygen species production, among others, interconnect to create a complex pathological network that worsens myocardial cell damage and leads to cardiac dysfunction symptoms. The limited effectiveness of current pharmacological treatments has increased the appeal of non-pharmacological therapies, especially exercise therapy. Exercise is anticipated to ameliorate diabetic myocardial disease through pleiotropic beneficial effects. The fundamental mechanisms behind these benefits remain unclear; further investigation of these mechanisms will aid in developing targeted therapies. This paper aims to explore how exercise affects myocardial metabolism, antioxidant capacity, fibrosis, and microangiopathy while providing an overview of key mechanisms and recent breakthroughs to encourage ongoing research in this area.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exosomal miR-320c: A Novel Biomarker for Atrial Cardiomyopathy.","authors":"Yangcheng Xue, Zhuoran Jia, Shichu Liang, Manyu Dai, Fang Liu, Jian Wu, Ren Zhao","doi":"10.1007/s12265-025-10627-w","DOIUrl":"https://doi.org/10.1007/s12265-025-10627-w","url":null,"abstract":"<p><p>Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaoying Zhao, Yujiao Song, Li Zhang, Lujing Wang, Xinxiang Zhao, Jin Wang
{"title":"Cardiac Magnetic Resonance-Derived Left Ventricular Mechanical Dispersion Improves Risk Stratification of Hypertrophic Cardiomyopathy and its Correlations with Scar Heterogeneity.","authors":"Xiaoying Zhao, Yujiao Song, Li Zhang, Lujing Wang, Xinxiang Zhao, Jin Wang","doi":"10.1007/s12265-025-10631-0","DOIUrl":"https://doi.org/10.1007/s12265-025-10631-0","url":null,"abstract":"<p><p>The accuracy of prevalent risk models recommended by American Heart Association/American College of Cardiology(AHA/ACC) and European Society of Cardiology(ESC) for hypertrophic cardiomyopathy(HCM) patients is suboptimal. We assessed the utility of cardiac magnetic resonance(CMR)-3D left ventricular mechanical dispersion(LVMD) in the prognostic stratification of 159 HCM and explore the correlation with myocardial fibrosis heterogeneity. Entropy demonstrated linear correlations with 3D LVMD. Patients experienced endpoint events exhibited significantly higher radial LVMD(LVMD-R), circumferential LVMD(LVMD-C), and longitudinal LVMD(LVMD-L). Kaplan-Meier analyses demonstrated that HCM patients with elevated LVMD had a higher risk of primary and secondary endpoint events. In multivariable Cox analysis incorporated the guidelines risk classification, both LVMD-C and LVMD-L emerged as significant predictors for endpoint events. We developed a model incorporated the 2022 ESC risk stratification in combination with LVMD-C and LVMD-L and revealed that combined model significantly outperformed the guidelines alone. Additionally, entropy demonstrated linear correlations with LVMD.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endothelial Glycocalyx Damage and Restoration Following Vascular Stent Implantation.","authors":"Belay Tesfamariam","doi":"10.1007/s12265-025-10633-y","DOIUrl":"https://doi.org/10.1007/s12265-025-10633-y","url":null,"abstract":"<p><p>The endothelial glycocalyx layer forms interface between the luminal surface and circulating blood, and consists of cell surface membrane-bound glycosaminoglycan chains and transmembrane embedded glycoproteins and proteoglycans, such as glypicans and syndecans. This dynamic layer contributes to various endothelial functions, including maintenance of vascular permeability, mechanosensation, shear-stress-mediated nitric oxide generation, modulation of interactions with constituents of blood, and regulation of vascular tone. Following vascular device placement, the transmembrane-linked glycosaminoglycan side chains are damaged and released into the circulation as soluble heparan sulfate, hyaluronan, and chondroitin sulfate. Damage to the glycocalyx causes an increase in vascular permeability, adhesion of leukocytes and platelets to the endothelium, extravasation of proinflammatory cells, dysregulation of vascular tone, imbalance of coagulation, and loss of antioxidant defense mechanisms. This review highlights the function of the endothelial glycocalyx as a vasoprotective layer and discusses targeted therapeutic approaches to promoting the restoration of glycocalyx disrupted by vascular stent implantation.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extracellular Vesicles as Diagnostic Metrics for Cardiovascular Disease: Where We are and How to Achieve in Clinics.","authors":"Yujia Wang, Yingxue Yuan, Junnan Tang","doi":"10.1007/s12265-025-10629-8","DOIUrl":"https://doi.org/10.1007/s12265-025-10629-8","url":null,"abstract":"<p><p>As one of the leading causes of death globally, early diagnosis and prevention of cardiovascular disease have become the focus of clinical and public health. Extracellular vesicles (EVs) are small, double-layered membrane structures actively secreted by cells and are widely present in body fluids such as blood, urine, and saliva. They carry various bioactive molecules, including proteins and nucleic acids, and are known for their remarkable stability and easy accessibility, making them promising candidates for identifying cardiovascular disease. This review summarizes the applications of EVs in the early diagnosis of cardiovascular disease, explores the potential biomarkers of proteins and RNAs (such as miRNA, lncRNA, and circRNA) contained within EVs, and discusses the prospects and challenges of EV biomarkers in clinical applications.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caiping Tan, Xiaoqi Chen, Lingqi Xu, Jiaping Chen, Yingbing Tu
{"title":"Targeting KDM4C Prevents Heart Failure after Acute Myocardial Infarction Via Activation of SOS2.","authors":"Caiping Tan, Xiaoqi Chen, Lingqi Xu, Jiaping Chen, Yingbing Tu","doi":"10.1007/s12265-025-10594-2","DOIUrl":"10.1007/s12265-025-10594-2","url":null,"abstract":"<p><p>Here, we focused on the function of SOS2 in heart failure (HF) after acute myocardial infarction (AMI) and investigated the mechanism. An oxygen-glucose deprivation (OGD) model in HL-1 cardiomyocytes and the ligation of the left anterior descending coronary artery in mice were conducted for MI modeling. SOS2 was downregulated in the heart tissues of mice with AMI. SOS2 activated the PI3K/Akt signaling, thereby alleviating cardiomyocyte apoptosis and inflammatory response, which were compromised by PI3K/Akt signaling inhibitor LY294002. Lysine-specific demethylase 4C (KDM4C) levels were downregulated in the heart tissue of AMI mice and OGD-induced HL-1 cells, accompanied by a reduction in H3K9Me3, while KDM4C overexpression triggered SOS2 expression by removing H3K9Me3 modification from its promoter. Knockdown of SOS2 abated the effects of KDM4C overexpression, thereby accentuating HF in mice. This study revealed that KDM4C protected mice against HF following AMI by restoration of SOS2 and the PI3K/Akt signaling.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":"498-511"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}